AVAGE (tazarotene) by Almirall is form, the carboxylic acid of tazarotene, by deesterification. Approved for retinoid [epc]. First approved in 2000.
Drug data last refreshed 20h ago · AI intelligence enriched 1w ago
AVAGE (tazarotene) is a topical retinoid cream approved in 2000 for treating skin conditions characterized by abnormal keratin formation and scaling. Tazarotene is metabolized to tazarotenic acid, which binds to retinoic acid receptors (RARα, RARβ, RARγ) with relative selectivity for RARβ and RARγ to modify gene expression. The exact clinical significance of its receptor selectivity profile remains incompletely characterized.
Product approaching loss of exclusivity with moderate competitive pressure (30/100), indicating potential team contraction and shift toward cost-containment and generic transition strategies.
form, the carboxylic acid of tazarotene, by deesterification. Tazarotenic acid binds to all three members of the retinoic acid receptor (RAR) family: RARα, RARβ, and RARɣ, but shows relative selectivity for RARβ, and RARɣ and may modify gene expression. The clinical significance of these findings…
Retinoid
Indication data is being enriched from DailyMed and FDA labeling. Check back soon for approved therapeutic uses.
Traumatic Hemothorax Drainage and Daily Lavage
Chlorhexidine Lavage for Recurrent Urinary Tract Infection
Does Joint Lavage Reduce Intraarticular Inflammation in High-energy Tibial Pilon Fractures?
Combination of Halobetasol Propionate and Tazarotene Lotion (Duobrii®) for Palmoplantar Plaque Type Psoriasis
Liquid Biopsy for ctDNA in Peritoneal Lavage and Blood in Pancreatic Cancer
Worked on AVAGE at Almirall? Share your interview experience or compensation data (+7 days Pro)
The information on this page is for informational purposes only and should not be used as a substitute for professional medical advice. Drug information is sourced from FDA, DailyMed, and other government databases. Adverse event data from FAERS does not establish causation. Always consult a healthcare professional for medical decisions.
Working on AVAGE offers limited career growth opportunity given its LOE-approaching status and mature lifecycle stage. Roles focus on managing market decline, generic transition, and maximizing remaining branded sales through cost-containment and access optimization rather than growth initiatives.